The independent source for health policy research, polling, and news.
281 - 300 of 1,299 Results
In November, the Centers for Disease Control and Prevention released new guidelines for prescribing opioids for pain, allowing physicians more flexibility. But doctors, patients, and advocates wonder if the updated standards will be too little, too late to help chronic pain patients in a country still focused on fighting the ongoing opioid crisis.
Very little in the proposed budget released by the Biden administration is likely to become law, particularly with Republicans in charge of the U.S. House. Still, the document is an important statement of the presidents policy priorities, and its clear health programs are among those he feels are important. Meanwhile, five women who were denied abortions when their pregnancies threatened their lives are suing Texas. Shefali Luthra of The 19th, Victoria Knight of Axios, and Margot Sanger-Katz of The New York Times join KHNs Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Harris Meyer, who reported and wrote the two latest KHN-NPR Bill of the Month features. Both were about families facing unexpected bills following childbirth.
Big Pharma may be moving on from squeezing diabetes patients on insulin prices, but its the arbitrators that jack up prices for those who can least afford them.
Under pressure from Republican attorneys general, the nation's second-largest pharmacy chain says it will not dispense the abortion pill mifepristone.
The FDA has long blocked the importation of cheap medicine, agreeing with pharmaceutical manufacturers that it opens the door to opioids. The agencys own data shows that rarely happens.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Heres a collection of their appearances.
President Joe Biden and Republicans in Congress spent last month sparring over whether to shield Medicare and Social Security from budget cuts leading some to wonder if Medicaid was on the table instead. Biden and Democrats say no, but some Republicans seem eager to trim federal spending on the health program for Americans with low incomes. And ready or not, artificial intelligence is coming to medical care. Benefits, as well as unintended consequences, are likely. Alice Miranda Ollstein of Politico, Rachel Cohrs of STAT News, and Lauren Weber of The Washington Post join KHNs chief Washington correspondent, Julie Rovner, to discuss these issues and more.
Eli Lilly's news that it plans to cut insulin costs for patients will help, not hinder, the recent efforts in California and by entrepreneurs such as Mark Cuban to offer lower-cost alternatives, drug pricing experts said.
KHN gives readers a chance to comment on a recent batch of stories.
Colorados proposed legislation to cap the copay for the EpiPen is part of a nationwide trend as more states try to shield patients from skyrocketing drug prices.
What happens in Texas doesn't stay in Texas, warns an abortion rights advocate bracing for a district judges ruling on whether the abortion pill mifepristone was properly authorized by the FDA. His decision could force the medication off the U.S. market.
Patients who depend upon special drugs to treat rare diseases are caught in the crossfire as drugmakers and the FDA battle over regulations that reward companies for developing treatments for relatively small pools of patients.
The billionaire entrepreneur and NBA team owner is making waves with his new drug company. But his generics arent always the lowest-priced deal.
A new survey from the Centers for Disease Control and Prevention finds that teenagers, particularly girls, are reporting all-time high rates of violence and profound mental distress. Meanwhile, both sides in the abortion debate are anxiously waiting for a district court decision in Texas that could effectively revoke the FDAs 22-year-old approval of the abortion pill mifepristone. Alice Miranda Ollstein of Politico, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHNs chief Washington correspondent, Julie Rovner, to discuss these issues and more.
The veterinary tranquilizer xylazine, the choice du jour of local drug dealers to cut fentanyl, leads to necrotic ulcers and leaves street medics and physicians confused about how best to deal with this wave of the opioid crisis.
Twitter has been a hotbed for the burgeoning insulin access movement and activism surrounding other medical conditions. For people with diabetes, the platform has helped propel concern about insulin prices into policy. Can it continue to win with hashtags?
When Medicare stops paying for a pricey drug that prolongs life, an Ohio man considers giving up treatment to spare his family enormous debt.
Insurers, employers, and taxpayers will all be affected as drug manufacturers move these products to the commercial market.
President Joe Bidens 2023 State of the Union address leaned heavily on health care issues. Biden took a victory lap for recent accomplishments like capping prescription drug costs for seniors on Medicare. He also urged Congress to make permanent the boosted premium subsidies under the Affordable Care Act, and he sparred with Republicans on threats to cut Social Security and Medicare. Also this week, both sides in the abortion debate are bracing for a court decision out of Texas that could, at least temporarily, make the abortion pill mifepristone illegal nationwide. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Kate Baicker of the University of Chicago about a possible middle ground in the effort to get universal health insurance coverage.
The nations largest Medicaid insurer denies wrongdoing after the California attorney generals office investigated it for inflating prescription drug costs.
穢 2026 KFF